

AMENDMENTS TO THE CLAIMS

Claims 1-72 (Cancelled).

73. (Currently amended) ~~The solid composition of claim 72~~ A solid composition comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

74. (Cancelled)

75. (Currently amended) ~~The solid composition of claim 72~~ A solid composition comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein about 0.1% to about 10% of at least one pharmaceutically acceptable antioxidant is present.

76-79. (Cancelled)

80. (Currently amended) ~~The solid composition of claim 79~~ A solid composition comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight, wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

81. (Currently amended) ~~The solid composition of claim 79~~ A solid composition comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight, wherein about 0.1% to about 10% of at least one pharmaceutically acceptable antioxidant is present.

82-89. (Cancelled)

90. (Currently amended) ~~The solid composition of claim 89~~ A solid composition comprising about 5 mg of desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight, wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

91-92. (Cancelled)

93. (Previously presented) A solid composition whose ingredients comprise:

INGREDIENT	mg/composition
Desloratadine, micronized	5.0
Corn Starch NF/Ph. Eur.	36.0
Microcrystalline Cellulose NF/Ph. Eur./JP	132.7
Edetate Disodium USP	10.0
Citric Acid Anhydrous, USP	10.0
Stearic Acid, NF.	6.0
Dye	0.3
TOTAL	200.0

wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

94. (Previously presented) The solid composition of claim 93 wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

95. (Previously presented) A solid composition whose ingredients comprise:

INGREDIENT	mg/composition
Desloratadine, micronized	2.5
Corn Starch NF/Ph. Eur.	18.0
Microcrystalline Cellulose NF/Ph. Eur./JP	66.35
Edetate Disodium	5.0
Citric Acid	5.0

Stearic Acid USP/Ph. Eur.	3.0
Dye	0.15
TOTAL	100.00

and wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

96. (Previously presented) The solid composition of claim 95 wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

97. (Cancelled)

98. (Cancelled)

99. (Currently amended) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of ~~claim 72~~, claim 75.

100. (Cancelled)

101. (Currently amended) ~~The solid composition of claim 100~~ A solid composition comprising an anti-allergic effective amount of desloratadine and a desloratadine-protective amount of two pharmaceutically acceptable antioxidants, wherein total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight, wherein the two pharmaceutically acceptable antioxidants are edetate disodium and citric acid.

102-104. (Cancelled)

105. (Currently amended) ~~The solid composition of claim 103~~ A solid composition comprising about 2.5 mg desloratadine and a desloratadine-protective amount of at least one pharmaceutically acceptable antioxidant, wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

106. (Previously presented) A solid composition whose ingredients comprise:

INGREDIENT	mg/composition
Desloratadine, micronized	5.0
Corn Starch NF/Ph. Eur.	36.0
Microcrystalline Cellulose NF/Ph. Eur./JP	140.7
Edetate Disodium	10.0
Citric Acid	2.0
Talc NF/Ph. Eur.	6.0
Dye	0.3
TOTAL	200.0

wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

107. (Previously presented) The solid composition of claim 106 wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

108. (Previously presented) A solid composition whose ingredients comprise:

INGREDIENT	mg/composition
Desloratadine, micronized	2.5
Corn Starch NF/Ph. Eur.	18.0
Microcrystalline Cellulose NF/Ph. Eur./JP	70.35
Edetate Disodium	5.0
Citric Acid	1.0
Talc NF/Ph. Eur.	3.0
Dye	0.28
TOTAL	100.00

wherein the total amount of desloratadine degradation products in the solid composition is less than or equal to 2% by weight.

109. (Previously presented) The solid composition of claim 108 wherein at least 80% of the desloratadine dissolves in a 0.1N HCl solution at 37° C in about 45 minutes.

110-116. (Cancelled)

117. (Currently amended) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of ~~claim 102~~, claim 101.

118. (Currently amended) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of ~~claim 103~~, claim 105.

119. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 106.

120. (Previously presented) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 108.

121. (New) A method of treating the nasal and non-nasal symptoms of perennial or seasonal allergic rhinitis which comprises administering to a patient in need of such treating an effective amount of the solid composition of claim 73.